Short answer
ANI PHARMACEUTICALS INC (ANIP) filed an 8-K current report with the SEC on November 5, 2026 reporting Item EX-99.4 (Exhibit EX-99.4), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). $676 million 364-day senior bridge facility supporting ANI’s proposed cash offer for Egetis Therapeutics.
ANI PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $676 million 364-day senior bridge facility supporting ANI’s proposed cash offer for Egetis Therapeutics
- Facility also earmarked to refinance ANI’s existing term loans and certain Egetis indebtedness
- Initial interest margins: 1.75% over ABR or 2.75% over adjusted term SOFR
- Initially unsecured, becoming secured by substantially all company and certain subsidiary assets upon funding
- Short maturity and security package increase refinancing and leverage risk if the Egetis transaction closes
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 points to Item 1.01 for the underlying borrowing or financial obligation details
- Investor impact depends on the referenced agreement’s amount, pricing, maturity, and purpose
Item 8.01 · Other Events
- Recommended cash offer for Egetis: SEK 5.6B, approximately $559.9M total consideration
- Consideration: SEK 11.25 per share, SEK 65,750,817 for the Convertible, and SEK 6.99 per Warrant
- Egetis board recommendation and 42.2% shareholder commitments materially improve transaction certainty
- Closing requires at least 90% fully diluted tender acceptance and regulatory, governmental, and competition clearances
- Above 90% ownership could trigger compulsory redemption and Egetis delisting from Nasdaq Stockholm
Item EX-99.1 · Exhibit EX-99.1
- ANI is preparing a voluntary cash offer for Egetis Therapeutics at SEK 11.25 per share
- Proposed consideration also includes SEK 65,750,817 per convertible and SEK 6.99 per warrant
- An unnamed shareholder has irrevocably committed to tender its shares, strengthening transaction support
- Commitment expires if the offer is not announced by November 30, 2026, or declared unconditional by March 31, 2027
- Shareholder can withdraw if a competing bid exceeds ANI’s price by more than 5%, unless ANI matches or exceeds it
Item EX-99.2 · Exhibit EX-99.2
- Recommended acquisition of Egetis for approximately SEK 5.6B, or $560M, financed with cash on hand and new JPMorgan debt
- Net enterprise value approximately $434M after Egetis’ planned $190.0M PRV sale and related earn-out obligations
- EMCITATE approved in U.S. and Europe, with over $300M peak-sales potential and patent protection into 2045
- Offer price SEK 11.25 per share, a 27% premium to Egetis’ 60-day VWAP
- Closing requires at least 90% shareholder acceptance and regulatory approvals, with the offer period expected November 20 to December 18, 2026
Item EX-99.3 · Exhibit EX-99.3
- Recommended cash acquisition of Egetis for approximately SEK 5,304 million, expanding ANI’s rare-disease platform with EMCITATE
- Offer price SEK 11.25 per share, premiums of 12.6% to last close, 27.0% to 60-day average and 48.0% to 180-day average
- Egetis’ EMCITATE received FDA approval September 28, 2026, with U.S. launch potential and a Rare Pediatric Disease Priority Review Voucher
- 42.2% shareholder support and unanimous Egetis board recommendation materially strengthen transaction certainty
- Funding combines cash on hand and JPMorgan debt, with acceptance expected November 20 to December 18, 2026 and completion requiring over 90% ownership
Item EX-99.4 · Exhibit EX-99.4
- Egetis board unanimously recommends ANI’s SEK 5,304 million cash offer, supporting ANIP’s acquisition of a commercial-stage rare-disease platform
- Consideration: SEK 11.25 per share, SEK 65,750,817 for the EUR 3 million convertible, and SEK 6.99 per warrant
- Offer premiums: 12.6% to last close, 27.0% to 60-day average, and 48.0% to 180-day average
- Shareholder undertakings cover 196,127,092 shares, approximately 42.2% of outstanding shares, materially improving deal certainty
- Completion requires over 90% ownership on a fully diluted basis and regulatory clearances, with acceptance expected from 20 November to 18 December 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANI PHARMACEUTICALS INC 8-K filings
Get the next ANIP 8-K as it lands
Follow ANIP for push alerts, or ask the research agent what this filing means.